Presentation is loading. Please wait.

Presentation is loading. Please wait.

Regorafenib inhibits angiogenesis and induces apoptosis.

Published byGillian Ryan Modified over 4 years ago

Similar presentations

Presentation on theme: "Regorafenib inhibits angiogenesis and induces apoptosis."— Presentation transcript:

1 Regorafenib inhibits angiogenesis and induces apoptosis.
Regorafenib inhibits angiogenesis and induces apoptosis. A, quantification of VEGFR2+/CD31 reveals the strongest decrease in the angiogenic activity in the regorafenib-treated tumors, showing a significant decrease on day 11 (*, P < 0.05; n = 4) and 14 postimplantation (**, P < 0.01; n = 6) compared with the vehicle-treated animals. DC101 significantly reduces the angiogenic activity compared with the controls on day 14 postimplantation (**, P < 0.01; n = 6). B, representative immunostainings of tumors on day 14 postimplantation; CD31 (green), VEGFR2 (red), nuclei (blue); bar, 50 μm. C, further quantification of TIE2+/CD31 shows the lowest ratio in regorafenib-treated tumors on day 14 postimplantation. D, representative immunostainings of tumors on day 14 postimplantation; CD31 (green), TIE2 (red), nuclei (blue); bar, 50 μm. E, quantification of the TUNEL-positive area fraction shows the highest increase in apoptosis in the regorafenib-treated tumors on day 14 postimplantation (**, P < 0.01). F, representative immunostainings of tumors on day 14 postimplantation; CD31 (green), TUNEL (red), nuclei (blue); bar, 50 μm. N, necrotic/apoptotic areas. Data are presented as median ± interquartile range. Lotfi Abou-Elkacem et al. Mol Cancer Ther 2013;12: ©2013 by American Association for Cancer Research

Download ppt "Regorafenib inhibits angiogenesis and induces apoptosis."

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Activation of EphB4 by ephrinB2‐Fc prevents aberrant angiogenesis

Activation of EphB4 by ephrinB2‐Fc prevents aberrant angiogenesis
AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.
18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.
Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.

Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.
Immunologic responses after the MN-mediated cancer immunotherapy.

Immunologic responses after the MN-mediated cancer immunotherapy.
Macrophage-specific ablation of Vegfa in PyMT implant tumors blocks blood vessel permeability and tumor cell intravasation at the TMEM. A and C, immunofluorescence.

Macrophage-specific ablation of Vegfa in PyMT implant tumors blocks blood vessel permeability and tumor cell intravasation at the TMEM. A and C, immunofluorescence.
IL32 prompts cell activation and cancer-related pathways.

IL32 prompts cell activation and cancer-related pathways.
Tregs and APC subsets in TDLNs of patients with cervical cancer.

Tregs and APC subsets in TDLNs of patients with cervical cancer.
Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.
Inhibition of VEGFA or macrophage-specific ablation of Vegfa from TIE2hi/VEGFAhi TMEM macrophages reduces vascular permeability and tumor cell intravasation.

Inhibition of VEGFA or macrophage-specific ablation of Vegfa from TIE2hi/VEGFAhi TMEM macrophages reduces vascular permeability and tumor cell intravasation.
Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.

Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.
mpJX-594 effects on tumor burden and leukocyte influx.

mpJX-594 effects on tumor burden and leukocyte influx.
Quantification of MHC-I, β2m, and T-cell subsets.

Quantification of MHC-I, β2m, and T-cell subsets.
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
A: Total collagen content by Sirius red staining in cardiac tissue of control (SD) animals. A: Total collagen content by Sirius red staining in cardiac.

A: Total collagen content by Sirius red staining in cardiac tissue of control (SD) animals. A: Total collagen content by Sirius red staining in cardiac.
Box plot of acquisition times across the various study cohorts.

Box plot of acquisition times across the various study cohorts.

Similar presentations

Ads by Google